Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice

Canadian Journal of Physiology and Pharmacology

Volumn 79, Issue 6, 2001, Pages 533-544

  Saadane, N ^a   Yue, P ^a   Alpert, L ^a   Mitmaker, B ^a   Kirby, G M ^a   Chalifour, L E ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cardioprotection; DNA topoisomerase II inhibitors; Doxorubicin; Gene expression; Mice

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CELL PROTEIN; COMPLEMENTARY DNA; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; ETOPOSIDE; GYRASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN NAB 1; PROTEIN NAB 2; PROTEIN NKX2; RAZOXANE; TRANSCRIPTION FACTOR GATA 4; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENOTYPE; HEART MUSCLE; HEART PROTECTION; HEART WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOVASCULAR AGENTS; DNA; DNA-BINDING PROTEINS; DOXORUBICIN; EARLY GROWTH RESPONSE PROTEIN 1; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION; IMMEDIATE-EARLY PROTEINS; MICE; PHENOTYPE; RAZOXANE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 0034886254     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/cjpp-79-6-533     Document Type: Article

References (89)

1. Evaluation of anthracycline cardiotoxicity: Predictive ability and functional correlation of endomyocardial biopsy
2. DNA topoisomerase II-mediated interaction of doxorubicin and daunoribicin congeners with DNA
3. Isolation, characterization, and expression of the murine Wilm's tumor gene (WT1) during kidney development
4. Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children
5. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes
6. Polyomavirus large T-antigen expression in heart of transgenic mice causes cardiomyopathy
7. A gene encoding a protein with zinc fingers is activated during G0/G1 transition in cultured cells
8. The clinical pharmacology of etoposide and teniposide
9. Toxic mechanisms of the heart: A review
10. The early response gene NGF1-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family
11. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and Egr-1
12. R, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity
13. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin
14. The cardiac transcription factors Nkx2.5 and GATA-4 are mutual cofactors
15. Cellular origin and distribution of transforming growth factor-beta 1 expression in rat ventricular myocytes
16. Early growth response protein 1 (Egr-1): Prototype of a zinc-finger family of transcription factors
17. Epidemiology of anthracycline cardiotoxicity in children and adults
18. Cardiac myocytes and fibroblasts contain functional estrogen receptors
19. Expression of oestrogen receptor α and β in rat heart: Role of local oestrogen synthesis
20. Cumulative cytostatic effect of ICRF-159
21. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction
22. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane), its hydrolysis product ICRF-198, and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin
23. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its hydrolysis product ADR-925
24. Chemical, biological and clinical aspects of Dexrazoxane and other bisdioxopiperazines
25. Overview and historical development of dexrazoxane
26. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
27. Molecular remodeling in hypertrophied hearts from polyomavirus large T-antigen transgenic mice
28. Morphometry and muscle gene expression in hypertrophied hearts from polyomavirus large T antigen transgenic mice
29. Reciprocal modulation between Sp1 and Egr-1
30. Dose-response relationship of Dexrazoxane for prevention of Doxorubicin-induced cardiotoxicity in mice, rats and dogs
31. Genetic decreases in atrial natriuretic peptide and salt sensitive hypertension
32. Myocardial reperfusion injury: Insights gained from gene-targeted mice
33. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice
34. Early growth response factor 1: A pleiotropic mediator of inducible gene expression
35. Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells
36. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts
37. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
38. Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A
39. Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and 5-fluoracil
40. Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGF1-A
41. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGF1-A (Egr-1)
42. Unimpaired macrophage differentiation and activation in mice lacking the zinc finger transcription factor NGF1-A (Egr1)
43. Natriuretic peptides
44. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by Probucol
45. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction
46. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
47. Suppression of growth and transformation and induction of apoptosis by Egr-1
48. Myogenic and morphogenetic defects in heart tubes of murine embryos lacking the homeobox gene Nkx2.5
49. Hormonal induction of an immediate-early gene response in myogenic cell lines - A paradigm for heart growth
50. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells
51. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: A phase II study from the Société Francaise d'Oncologie Pediatrique
52. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor
53. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium
54. Promoter elements of the mouse acetylcholinesterase gene. Transcriptional regulation during muscle differentiation
55. The role of iron in Doxorubicin-induced cardiomyopathy
56. Cardiomyocyte differentiation by GATA-4-deficient stem cells
57. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes
58. Functional activation of the Egr-1 (early growth response-1) gene by hydrogen peroxide
59. Molecular biology of cardiac growth and hypertrophy
60. EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factor
61. Proximal regulatory domains of atrial natriuretic factor gene
62. Identification of NAB1, a corepressor of NGF1-A and Krox-20-mediated transcription
63. TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin
64. Expression of immediate early genes, GATA-4, and Nkx2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice
65. Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice
66. Etoposide phosphate: What, why, where, and how?
67. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,4-dioxopiperaz9nyl-1yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP16)
68. GATA-4 and Nkx2.5 coactivate Nkx-2 DNA binding targets: Role for regulating early cardiac gene expression
69. Anthracycline-induced cardiotoxicity
70. Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3
71. Adriamycin cardiomyopathy: Pathophysiology and prevention
72. The role of oxidative stress in the genesis of heart disease
73. Coordinate expression and distinct DNA-binding characteristics of the four EGR-zinc finger proteins in Jurkat T lymphocytes
74. Cardiomyocyte DNA synthesis and binucleation during murine development
75. Strategies for reduction of anthracycline cardiac toxicity
76. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: A series of 15 patients
77. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute nonlymphocytic leukemia (ANLL): A pilot study
78. NAB-1, a co-repressor of NGF1-A (Egr-1) and Krox-20, is induced by proliferative and differentiative stimuli
79. Multiple pituitary and ovarian defects in Krox-24 (NGF1- A, Egr-1)-targeted mice
80. Myocardial diseases of animals
81. Dexrazoxane (ICRF-187)
82. High-dose cytosine arabinoside and etoposide: An effective regimen without anthracyclines for refractory childhood acute non-lymphocyte leukemia
83. High dose folinic acid/etoposide/5-fluorouacil in advanced gastric cancer: A phase II study in elderly patients or patients with cardiac risk
84. Dexrazoxane; A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy
85. Proliferation and cell cycle dependent differences in the expression of the 170 kD and 180 kD forms of topoisomerase II in NIH 3T3 cells
86. Molecular mechanism of cardiac cellulr hypertrophy by mechanical stress
87. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia
88. The full induction of apoprotein A-1 gene expression in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1